Managing diabetes in a ‘flash’

Not Applicable

Completed

• Conditions: Type 1 diabetes; Metabolic and Endocrine - Diabetes

• Registration Number: ACTRN12618000320257
• Lead Sponsor: Department of Women's and Children's Health, DSM

Brief Summary

For youth with high-risk glycemic control, flash glucose monitoring led to improvements in glucose testing frequency and diabetes treatment satisfaction. However, these did not translate to greater improvement in glycaemic control over usual care with self-monitoring blood glucose at 6 months.

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2018-03-05
• Study Completion: 2019-10-15
• Last Update Posted: 9 November 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 64

Inclusion Criteria

1) aged 13 to 20 years, inclusive;
2)diagnosed with T1D for at least 12 months;
3)mean HbA1c of >= 75 mmol/mol over the past 6 months;
4)>0.5 units of insulin/kg/day (with no restrictions based on insulin regimen);
5)plans to continue with routine clinical care during the 6-month study;
6)currently residing in and expecting to remain in regions served by the Canterbury, Capital and Coast, South Canterbury, and Southern District Health Boards for the following year;
7)the ability to understand study procedures and to comply with them for the entire length of the study.

Exclusion Criteria

1)Any severe diabetes related complications (nephropathy on treatment, retinopathy with associated visual loss – milder degrees will not be excluded);
2)Other severe uncontrolled medical or psychiatric co-morbidity/severe mental illness;
3)currently using a CGM device or has used one continuously (other than for intermittent hospital use) within the previous 4 months;
4)participation in another device or drug study that could affect glucose measurements during the study period;
5)pregnancy, lactation, or plans to become pregnant;
6)inability of individual or legal guardian to give written informed consent.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Glycaemic control (as measured by HbA1c)[baseline, 3-, 6- (primary time point), 9-, and 12 months post-baseline. ]